LX1001 is being evaluated in an open‐label, dose‐escalation Phase 1/2 clinical trial in APOE ε4 homozygous individuals who are 50 years of age or older and have mild cognitive impairment (MCI) to moderate dementia and biomarkers consistent with AD. This evidence concerns the gene APOE and dementia.